AEterna Zentaris Inc. (AEZS)

[downtrendbuyer]

That is misleading information...

I will not comment on your link because that is not updated, but in general they must give priority to the evaluation of ZoptEC as follows: They cannot study the effects on two different types of cancer at the same, also no pharma (if not gigant) can produce such amount of drug for two simultanously ongoing study from different angles. They simply don't have enough resources to have full power on both Zoptarelin Doxorubicin for Endometrial cancer and Zoptarelin Doxorubicin for Ovarian cancer as well as on Castration and taxane-resistant prostate cancer. They must have priority on Zoptarelin Doxorubicin for Endometrial cancer now and later on the latter.


Your source is not even updated:
ClinicalTrials.gov Identifier:
NCT01240629
First received: June 30, 2010
Last updated: May 21, 2015
Last verified: May 2015

Why are you trying to provide misleading information? You seriously say you are here just for fun?